Latest Healthcare News

Recce Pharmaceuticals has secured a second Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to test its RECCE 327 Gel in burn wound infection models, underscoring growing military interest in its synthetic anti-infectives.

Memphasys Limited secures significant repeat orders from Hamad Medical Corporation, marking a pivotal expansion of its Felix™ system across the MENA region.

Biome Australia has partnered with Fullscript to distribute its Activated Probiotics range across Canada, complementing its existing wholesale network and marking a key step in its international growth.

Adheris Health has expanded its operating cost reduction program, aiming for more than 30% savings by FY27, while refocusing on high-growth pharmaceutical categories and enhancing its AI-powered patient engagement platform.

333D Ltd reports continued revenue growth in digital asset management and unveils a pioneering blockchain solution for MRI data storage, reinforcing its foothold in digital healthcare.

Oakridge International reports solid growth in healthcare technology revenues and product development progress, while navigating a potential legal claim from Teko International.

4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.

Pathkey.AI has completed a strategic review, bolstered its leadership team, and secured $3.5 million in funding to accelerate growth and broaden its AI platform's applications beyond clinical trials.

Adherium Limited has exceeded its 2025 shipment goals for its Hailie Smartinhaler devices, driven by rapid growth in remote patient monitoring activations and improved US Medicare reimbursement policies.

Constellation Technologies has broadened its IoT deployments into defence and healthcare sectors while improving its cash flow position in the December quarter.

IMEXHS Limited has reported a strong finish to FY25, delivering revenue and underlying EBITDA at the top end of its guidance, driven by robust software growth and expanding recurring revenue.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.